Researchers have developed an animal model mimicking HIV infection in infants, potentially allowing the development of therapeutics and interventions for the pediatric population.
Browsing: Basic > Drug Development
Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
In this interview we speak to Vincent Racaniello, Professor of Microbiology & Immunology, about his work on polio, picornaviruses and publicizing science through blogs and podcasts.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
A study of four Ebola therapeutics demonstrated that two drugs showed significantly improved survival rates, leading to the trial being halted early.
Coagulation factors, which normally function to clot blood, have been demonstrated to have antibacterial action against Gram-negative bacteria in vitro and in mouse models.
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.
In this infographic we give you a visual snapshot of the antibiotics introduced for gonorrhea and a timeline of when resistance was first identified, in addition to setting out some of the primary resistance mechanisms.
In this interview we speak to Daniella Lefteri about her research on modulating arbovirus infection by targeting mosquito saliva, and what avenues this could present for new antiviral treatments.